Transgenomic Posts 22 Percent Decline in PGx Business, but Predicts Segment 'Swell' in Coming Months

A Transgenomic official said the company has signed deals "for a number of significant high-value projects" with pharmaceutical firms, which promise to "swell the [segment to] $1.5 million or more in the second quarter, plus [bring in] significant revenues throughout the remainder of the year."

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.

Related Stories